International Journal For Multidisciplinary Research

E-ISSN: 2582-2160   •   Impact Factor: 9.24

A Widely Indexed Open Access Peer Reviewed Multidisciplinary Bi-monthly Scholarly International Journal

Call for Paper Volume 7, Issue 6 (November-December 2025) Submit your research before last 3 days of December to publish your research paper in the issue of November-December.
Submit Research Paper Join as a Reviewer

Plagiarism is checked by the leading plagiarism checker TurnItIn

Call for Paper

Volume 7 Issue 6
November-December 2025

Submit your research paper

Indexing Partners
Academia Advanced Sciences Index Bielefeld Academic Search Engine CiteSeer DRJI Google Scholar Independent Search Engine & Directory Network ISI (International Scientific Indexing) Issuu Mendeley Research Networks
RefSeek ResearcherId - Thomson Reuters ResearchGate Scirus Scribd Semantic Scholar UTeM - Universiti Teknikal Malaysia Melaka Wiki for Call for Papers WorldCat Zenodo

Atorvastatin in Contemporary Lipid Management: Pharmacovigilance Perspectives and Comparative Safety Analysis

Author(s) Omkar Balaji Kamble, Umme Roman Shaikh
Country India
Abstract Atorvastatin, a widely prescribed HMG-CoA reductase inhibitor, plays a pivotal role in managing hyperlipidemia and reducing cardiovascular risk. While generally well-tolerated, post-marketing pharmacovigilance data have identified a spectrum of adverse drug reactions ranging from mild gastrointestinal disturbances and transient liver enzyme elevations to rare but serious myopathy and rhabdomyolysis. Understanding these adverse events, their underlying mechanisms, and risk factors is critical for optimizing therapy and ensuring patient safety. Pharmacokinetic characteristics, including extensive hepatic metabolism via CYP3A4 and renal excretion of metabolites, contribute to potential drug–drug interactions and variable toxicity profiles across patient populations. Comparative safety analyses with other statins, such as simvastatin and rosuvastatin, highlight atorvastatin’s efficacy-to-safety balance and underscore the importance of individualized therapy, dose adjustment, and monitoring strategies in high-risk groups, including the elderly, patients with renal or hepatic impairment, and those receiving polypharmacy. This review synthesizes current evidence on atorvastatin’s pharmacovigilance profile, clinical implications of adverse events, monitoring requirements, and strategies to mitigate risk, providing a comprehensive guide for clinicians and researchers in contemporary lipid management.
Keywords Atorvastatin, HMG-CoA reductase inhibitor, pharmacovigilance, adverse drug reactions, myopathy, rhabdomyolysis, drug–drug interactions, lipid-lowering therapy, comparative safety, risk management.
Field Medical / Pharmacy
Published In Volume 7, Issue 6, November-December 2025
Published On 2025-11-27
DOI https://doi.org/10.36948/ijfmr.2025.v07i06.62146
Short DOI https://doi.org/hbdsmq
View / Download PDF File

Share this



E-ISSN 2582-2160
CrossRef

CrossRef DOI is assigned to each research paper published in our journal.

IJFMR DOI prefix is
10.36948/ijfmr

Downloads
Research Paper Format Copyright Permission Form and Undertaking Form Cover Page Vol 7 Isu 5Cover Page Vol 7 Isu 4Cover Page Vol 7 Isu 3

All research papers published on this website are licensed under Creative Commons Attribution-ShareAlike 4.0 International License, and all rights belong to their respective authors/researchers.

CC-BY-SA Open Access

About IJFMR
Fees & Payment
Current Issue
Publication Archive 		Submit Research Paper
Track Submission Status
Publication Guidelines
Publication Ethics
Peer Review & Plagiarism 		Join as a Reviewer
Editors & Reviewers
Reviewer Referral Program
Get Reviewer Membership Certi. 		Website/Journal Policies
Usage Policy
Content Policies
Privacy Policy
Contact Us +91-9687-828-838 editor@ijfmr.com